返回 Agendas
Closing Session: Conference Highlights and Panel Discussion
Session Chair(s)
Session Chair Invited, BSN, DDS
Manager
DIA, Switzerland
This panel discussion is meant to highlight the challenges and issues with the development of oligonucleotide-based products in general and as brought forth at this conference. The intention is to transform this discussion into action oriented objectives to address the regulatory and industry issues and challenges affecting us all.
Speaker(s)
Panelists
Saraswathy V. Nochur, PHD, MSC
Alnylam Pharmaceuticals, United States
Chief Regulatory Officer
James D. Thompson, PHD
Moderna Therapeutics , United States
CMC Therapeutic Area Lead
Arthur A. Levin, PHD
Avidity Biosciences, United States
Distinguished Scientist
Scott Henry, PHD
Ionis Pharmaceuticals, Inc., United States
Senior Vice President, Nonclinical Development
Ramesh Raghavachari, PHD
FDA, United States
Supervisor, Unit 3/DPQA IV/OPQA I/OPQ/CDER
Additional Panelists Invited
United States